Skip to content
Biotechnology

Completion of First Triage Test Clinical Validation Study

Cleo Diagnostics Limited asx.COV 3 mins read

Highlights

  • Results from the first clinical validation study of the CleoDX Triage Test, performed in a 334 patient cohort, have been published in the peer-reviewed journal “Cancers”

  • The article, entitled ‘A novel predictive multi-marker test for the pre-surgical identification of ovarian cancer’ provides a detailed overview of the high performance of Cleo’s ovarian cancer diagnostics test

  • The article concluded that Cleo’s ovarian cancer test:
    • Was highly accurate with 95% sensitivity1 / 95% specificity2;
    • Correctly discriminated malignant from benign samples; and
    • Out-performed and was superior to current clinical methods.

  • Peer-review provides important validation of Cleo’s technology and commercial strategy, targeting the surgical triage market where accurate and sensitive identification of malignant tumours is essential.

MELBOURNE, AUSTRALIA, 6 November, 2023: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of an article on its triage test for ovarian cancer.

PEER REVIEWED PUBLICATION
Cleo’s first clinical validation study for its ovarian cancer triage test has been published in the peer-reviewed international journal ‘Cancers’. The results confirm the high accuracy of the CleoDX Triage Test, which was independent of menopausal status, and showed that it out-performed the two most widely used clinical scoring systems (the “Risk of Malignancy Index” and “Risk of Malignancy Algorithm”) for discriminating benign from malignant ovarian disease.


A copy of the publication is available here:  https://www.mdpi.com/2072-6694/15/21/5267

Moreover, the CleoDX surgical triage test correctly identified 81% of early-stage cancer patients in the cohort.


Commenting on the publication, Cleo Chief Scientific Officer, Dr Andrew Stephens, said:

“These results confirm that our core technology is robust and accurate, and most importantly can identify cancers at an early stage. These results strongly support our planned further development of this core technology aimed at ovarian cancer screening in the longer term”.

CLEO Chief Executive, Richard Allman, added:
“This is an important step forward as we work towards our goal of an FDA approved triage test. I look forward to providing further updates to the market as we progress through our development program.”


The next step in development will confirm functionality of the commercially available kits in an independent clinical trial, the results of which will be submitted to the FDA for regulatory approval. Cleo anticipates commencement of this trial before the end of CY2023.


OPPORTUNITY FOR CLEO AND OVARIAN CANCER DIAGNOSTICS MARKET

At present there is no clinically routine pre-surgical method for reliable evaluation and differentiation of benign vs malignant ovarian cancer tumours. Radical surgery is the cornerstone of cancer management, with complete hysterectomy being the norm. Removal of the ovaries, however, predisposes women to multiple co-morbidities including increased risk of cardiovascular disease, dementia and certain cancers amongst others. There is a clear need to differentiate benign vs malignant cases pre-surgically to enhance patient outcomes.

Cleo has defined a staged execution strategy to deliver it’s simple blood test which is focused on three key markets across pre-surgical triage testing, high-risk/recurrence detection, and broader screening programs. Achieving a positive outcome here from a peer-reviewed publication, has a material impact on the Company’s pathway with respect to the initial triage market. The Company will now use the publication of its test performance to further define the scope of the triage market.


Figure 1: Ovarian cancer diagnostic markets targeted by Cleo

 

For media inquiries, please contact:

Elvis Jurcevic
Investor Relations
+614 08 268 271
ej@cleodx.com

 

 

1 Sensitivity refers to the ability of a test to correctly identify patients with the tested for disease (true positive rate).
2 Specificity refers to the ability of a test to correctly identify people without the tested for disease (true negative rate).

 

More from this category

  • Biotechnology, Medical Health Aged Care
  • 24/05/2024
  • 10:53
Neuroscience Research Australia

NeuRA CEO elected as 2024 Fellow of the Australian Academy of Science

Scientia Professor Matthew Kiernan AM CEO at Neuroscience Research Australia has been elected as a 2024 Fellow of the Australian Academy of Science,joining the…

  • Contains:
  • Biotechnology, Science
  • 23/05/2024
  • 07:49
Brandon Capital

Up to $5 million In Funding Available for Dementia and Cognitive Decline Innovations Through CUREator+

23 May 2024 Melbourne: The CUREator+ Dementia and Cognitive Decline incubator program, a partnership between Brandon BioCatalyst, ANDHealth and Dementia Australia, has opened its first funding round. Companies pioneering innovative health technologies to enhance the lives of individuals affected by dementia and cognitive decline are set to receive up to $5 million per project in non-dilutive project funding, a substantial boost for their innovative solutions. Funded by the Federal Government’s $20 billion Medical Research Future Fund (MRFF), the program aims to support the development of novel approaches, spanning therapeutics, diagnostics, assistive and medical devices and digital health technologies, that will…

  • Biotechnology, Seniors Interest
  • 20/05/2024
  • 13:23
Centre for Eye Research Australia, Cerulea Clinical Trials

New centre to bring more international eye clinical trials to Victoria and boost access to sight-saving therapies

A new clinical trial centre launched today in Melbourne will bring more international trials to Victoria and give people living with vision loss and blindness early access to sight-saving therapies.To mark World Clinical Trials Day, Victorian Deputy Premier and Minister for Medical Research, the Hon Ben Carroll, launched Cerulea Clinical Trials - a new specialist ophthalmic clinical trial facility established by the Centre for Eye Research Australia (CERA).Cerulea Clinical Trials is supported by a $10million investment from Breakthrough Victoria and is expected to deliver clinical trials to more than 2500 Victorians a year over the next decade and create 50…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.